Skip to main content

Market Overview

TeamHealth Management Unfazed By Envision-AmSurg Deal


Bank of America Merrill Lynch's Kevin Fischbeck pounded the table on his bullish rating on shares of TeamHealth Holdings Inc (NYSE: TMH) in a research note Monday morning.

Following Envision Healthcare Holdings Inc (NYSE: EVHC)'s deal for AmSurg, Fischbeck spent time with TeamHealth CFO David Jones last week. The BofA analyst noted "the company is not concerned with its two main competitors merging as it sees a lot of value in its unique capabilities of offering post-acute hospitalist services to its hospital customers."

Fischbeck highlighted "a full pipeline of deals" and focus on "operational improvement at IPCM."

"TMH will continue to do tuck-in deals and there could be regional groups that are for sale. There is still potential for further consolidation of larger players, e.g. ED or anesthesia operators backed by private equity," according to Fischbeck.

BofA Merrill maintained a Buy rating and $52 price objective on shares of TeamHealth.

Latest Ratings for TMH

Dec 2016JefferiesDowngradesBuyHold
Nov 2016Wells FargoDowngradesOutperformMarket Perform
Oct 2016Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for TMH
View the Latest Analyst Ratings


Related Articles (TMH)

View Comments and Join the Discussion!

Posted-In: Bank of America Kevin FischbeckAnalyst Color M&A News Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at